Bicycle Therapeutics plc

As of June 30, 2026, Bicycle Therapeutics plc carries a market capitalization of 296.01M, placing it among publicly traded companies globally. Its enterprise value stands at -199.38M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bicycle Therapeutics plc's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Bicycle Therapeutics plc has 69.81M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.82, and the price-to-book ratio stands at 0.58.

As of June 30, 2026, Bicycle Therapeutics plc maintains a current ratio of 12.08, meaning it holds 12.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.87, indicating elevated leverage, while an interest coverage ratio of -1,062.24 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bicycle Therapeutics plc posted a negative return on equity (ROE) of -32.30, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -26.47, reflecting losses generated across the asset base. The company generates approximately 209,426.86 in revenue per employee across its workforce of 292.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Bicycle Therapeutics plc recorded 1.73M in income tax expense. The company reported a pretax loss of -188.68M and -190.41M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Bicycle Therapeutics plc's stock has declined approximately 53.81% over the past 52 weeks. The 50-day moving average sits at 3.87, while the 200-day moving average is 4.65.

Over the twelve months ended June 30, 2026, Bicycle Therapeutics plc generated 61.21M in revenue and converted that into -190.41M in net income, yielding earnings per share of -2.74. EBITDA reached -205.01M, while operating income came in at -210.58M.

As of June 30, 2026, Bicycle Therapeutics plc holds 510.05M in cash and equivalents against 14.66M in total debt, resulting in a net debt position of -510.05M. Total book value stands at 510.26M, with working capital of 527.60M providing operational flexibility.

Bicycle Therapeutics plc produced -206.05M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.23M in capital expenditures, free cash flow totaled -208.28M - equivalent to -3.00 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -344.06 and net profit margin of -311.11 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -70.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.05, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bicycle Therapeutics plc shareholders.

As of June 30, 2026, Bicycle Therapeutics plc has an Altman Z-Score of -0.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.